Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
AstraZeneca’s (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Zacks.com featured highlights include: Alexion Pharmaceuticals, Adient, Affiliated Managers Group and General Motors
FDA approves Pfizer’s (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.